These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38796598)

  • 1. Oncofetal SNRPE promotes HCC tumorigenesis by regulating the FGFR4 expression through alternative splicing.
    Wu Q; Liao R; Miao C; Hasnat M; Li L; Sun L; Wang X; Yuan Z; Jiang Z; Zhang L; Yu Q
    Br J Cancer; 2024 Jul; 131(1):77-89. PubMed ID: 38796598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.
    He Q; Huang W; Liu D; Zhang T; Wang Y; Ji X; Xie M; Sun M; Tian D; Liu M; Xia L
    Theranostics; 2021; 11(12):5759-5777. PubMed ID: 33897880
    [No Abstract]   [Full Text] [Related]  

  • 3. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
    Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
    Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3.
    Chen D; Zhao Z; Chen L; Li Q; Zou J; Liu S
    Cell Death Dis; 2021 Jul; 12(8):722. PubMed ID: 34290239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.
    Gauglhofer C; Paur J; Schrottmaier WC; Wingelhofer B; Huber D; Naegelen I; Pirker C; Mohr T; Heinzle C; Holzmann K; Marian B; Schulte-Hermann R; Berger W; Krupitza G; Grusch M; Grasl-Kraupp B
    Carcinogenesis; 2014 Oct; 35(10):2331-8. PubMed ID: 25031272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β1 Promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR4 Expression.
    Huang J; Qiu M; Wan L; Wang G; Huang T; Chen Z; Jiang S; Li X; Xie L; Cai L
    Cell Physiol Biochem; 2018; 45(4):1690-1699. PubMed ID: 29490293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
    Poh W; Wong W; Ong H; Aung MO; Lim SG; Chua BT; Ho HK
    Mol Cancer; 2012 Mar; 11():14. PubMed ID: 22439738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1.
    Yuan JH; Liu XN; Wang TT; Pan W; Tao QF; Zhou WP; Wang F; Sun SH
    Nat Cell Biol; 2017 Jul; 19(7):820-832. PubMed ID: 28553938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
    Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
    Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
    Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
    Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver.
    Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
    Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
    J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-methyladenosine-modified oncofetal lncRNA MIR4435-2HG contributed to stemness features of hepatocellular carcinoma cells by regulating rRNA 2'-O methylation.
    Zhu Y; Xiao B; Liu M; Chen M; Xia N; Guo H; Huang J; Liu Z; Wang F
    Cell Mol Biol Lett; 2023 Oct; 28(1):89. PubMed ID: 37891494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.
    Xiang DM; Sun W; Zhou T; Zhang C; Cheng Z; Li SC; Jiang W; Wang R; Fu G; Cui X; Hou G; Jin GZ; Li H; Hou C; Liu H; Wang H; Ding J
    Gut; 2019 Oct; 68(10):1858-1871. PubMed ID: 31118247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets.
    Liu M; Yan Q; Sun Y; Nam Y; Hu L; Loong JH; Ouyang Q; Zhang Y; Li HL; Kong FE; Li L; Li Y; Li MM; Cheng W; Jiang LX; Fang S; Yang XD; Mo JQ; Gong YF; Tang YQ; Li Y; Yuan YF; Ma NF; Lin G; Ma S; Wang JG; Guan XY
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6103-6113. PubMed ID: 32123069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
    Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
    BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
    Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
    J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.